Bromelain — Research Profile

GDU is an enzyme-activity measure. Distinguish activity per gram from activity per capsule or serving: for example, 500 mg of material labeled 2,400 GDU per gram corresponds to 1,200 GDU for that amount. Product mass alone does not identify activity, and the same activity number does not establish equivalent clinical benefit. ^[1]

The cited studies do not establish that fasting produces better systemic outcomes than taking bromelain with food. Digestive activity and measurable blood enzyme activity are not proof of a clinically superior schedule. Follow the specific product instructions and clinician advice. ^[6,9]

There is no reliable universal onset. Studies differ by procedure, preparation and outcome, and the pediatric sinusitis cohort cannot establish a causal recovery timeline. Ask the treating team about postoperative swelling rather than relying on a supplement timetable. ^[2,6]

Stem bromelain, extracted from the pineapple stem rather than the fruit, is the form used in most clinical trials and is taken orally as capsules or tablets. For burn care, bromelain is instead applied topically by clinicians to speed wound debridement, which is a different route from the oral supplement. There is no evidence that any single branded oral form outperforms another.

The best-supported oral benefit is modest: a 2023 meta-analysis found a small but statistically significant pain reduction (mean difference -0.27 on pain score) and possible benefit for sinusitis, but no benefit for cardiovascular disease. Topical bromelain is well established for speeding burn-wound debridement, cutting time to complete debridement by roughly 6.9 days. Its anti-inflammatory effects, such as lowering IL-1beta, IL-6, and TNF-alpha, are demonstrated mainly in laboratory cell studies rather than confirmed clinical endpoints.

No standardized daily dose has been established; a 2005 osteoarthritis review explicitly concluded that trials are still needed to determine the optimum dosage. Studies have used varied preparations and durations, from a bromelain-containing enzyme combination taken over 6 weeks for knee osteoarthritis to Bromelain-POS for pediatric sinusitis, without a single agreed regimen. Because potency is measured in enzyme activity, compare products by their GDU or MCU rating rather than by milligrams alone.

Timing has not been directly compared in the cited evidence. Oral absorption does not prove equal or better clinical effects with a particular meal schedule. Follow the product and clinician instructions rather than assuming between-meal dosing is established. ^[6]

Oral studies reported digestive symptoms such as flatulence and nausea, and headache. Allergic reactions have occurred, including a mild reaction in the sinusitis cohort. The systematic review did not establish major treatment-related risks, but it included serious events during topical treatment with uncertain relevance; short studies cannot exclude serious harm. Oral supplements and topical debridement should be assessed separately. ^[2,6,9]

MSK notes possible increased tetracycline exposure, laboratory CYP2C9 inhibition and preclinical bleeding concerns with anticoagulants. The clinical significance of the latter mechanisms is uncertain. Discuss blood thinners, antibiotics and planned procedures with a clinician before using it. ^[9]

Evidence for oral pain or sinusitis relief is limited and does not establish a first-line treatment. The pediatric cohort is not a basis for self-treating a child, and topical burn debridement is medical care. Pineapple allergy, blood thinners and planned procedures warrant particular caution. ^[1,2,6,9]

Trials evaluate different outcomes over days or weeks. The 116-child sinusitis study was observational, and the six-week arthritis trial used a combination product. Neither establishes a predictable onset for oral bromelain alone. ^[2,3]

Most bromelain trials are short, such as a 6-week comparison against diclofenac in knee osteoarthritis. A 2023 systematic review of 54 studies reported no major health risks and only mild effects like flatulence, nausea, and headache, but did not establish long-term safety. A 2005 osteoarthritis review specifically flagged the lack of prospective adverse-event monitoring for chronic use, so daily safety beyond a few weeks has not been formally demonstrated.

No established upper intake limit or reliable toxic threshold is available. Short trials with few serious events cannot rule out allergy, interactions or harm at higher doses. More enzyme activity is not evidence of greater benefit. ^[1,6,9]

A studied bromelain/trypsin/rutosid combination is not evidence for every supplement stack. Possible bleeding interactions and allergy need individual assessment, and absence of documented interactions does not establish safety. ^[3,9]

Bromelain potency is defined by enzyme activity rather than milligram weight, so choose a product that lists an activity level (GDU or MCU) alongside the mg amount. Bromelain is a cysteine protease isolated from the stem of the pineapple (Ananas comosus), and this stem-derived form is what most clinical work has used; the proteolytic pineapple enzyme Bromelain-POS studied in the pediatric sinusitis trials is one such preparation. Since no standardized dose is established, prioritize a clearly stated, verifiable activity level and third-party quality testing over headline milligram claims.